Role of circular RNA in the development, progression, diagnosis, and treatment of hepatocellular carcinoma

Shuying MIAO; Jun YANG; Wenyan GUAN; Biao ZHANG; Lu HE; Zhiwen FAN

doi:10.3969/j.issn.1001-5256.2023.08.033

Volume 39 Issue 8

Aug. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(8): 1983-1991

PDF( 1709 KB)

Role of circular RNA in the development, progression, diagnosis, and treatment of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.08.033

Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China

Research funding:

The National Natural Science Foundation of China (81700554);

The National Natural Science Foundation of China (82170592)

More Information

Corresponding author: FAN Zhiwen, fanzhiwenfff@126.com (ORCID: 0000-0002-3465-4622)
Received Date: 2022-10-27
Accepted Date: 2022-12-17
Published Date: 2023-08-20

Abstract

Abstract

As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) is an invasive and fatal malignant tumor, and its development and progression involve multiple genes, steps, and stages. Circular RNA (circRNA), as a class of endogenous non-coding RNAs, mainly acts as a sponge by absorbing microRNA or RNA-binding proteins to regulate the expression of downstream target genes. This article comprehensively introduces the role and significance of circRNA in signal transduction, immunity, metabolism, drug resistance, and hepatitis B virus-related HCC and its potential value as a biomarker or therapeutic target for HCC, so as to provide new ideas for the diagnosis and treatment of HCC.
- RNA, Circular,
- Carcinoma, Hepatocellular,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(53)

References

[1]	ZENG C, ZHANG L, LUO C, et al. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment[J]. BMC Cancer, 2022, 22(1): 613. DOI: 10.1186/s12885-022-09647-5.
[2]	CAI P, ZHENG H, SHE J, et al. Molecular mechanism of aflatoxin-induced hepatocellular carcinoma derived from a bioinformatics analysis[J]. Toxins (Basel), 2020, 12(3): 203. DOI: 10.3390/toxins12030203.
[3]	KHASHKHASHI MOGHADAM S, BAKHSHINEJAD B, KHALAFIZADEH A, et al. Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma[J]. J Cell Mol Med, 2022, 26(2): 287-305. DOI: 10.1111/jcmm.17126.
[4]	SANGER HL, KLOTZ G, RIESNER D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures[J]. Proc Natl Acad Sci U S A, 1976, 73(11): 3852-3856. DOI: 10.1073/pnas.73.11.3852.
[5]	LOUIS C, LECLERC D, COULOUARN C. Emerging roles of circular RNAs in liver cancer[J]. JHEP Rep, 2022, 4(2): 100413. DOI: 10.1016/j.jhepr.2021.100413.
[6]	HU ZQ, ZHOU SL, LI J, et al. Circular RNA sequencing identifies CircASAP1 as a key regulator in hepatocellular carcinoma metastasis[J]. Hepatology, 2020, 72(3): 906-922. DOI: 10.1002/hep.31068.
[7]	LIN Y, HUANG G, JIN H, et al. Circular RNA Gprc5a promotes HCC progression by activating YAP1/TEAD1 signalling pathway by sponging miR-1283[J]. Onco Targets Ther, 2020, 13: 4509-4521. DOI: 10.2147/OTT.S240261.
[8]	WU W, ZHOU Z, CHEN C, et al. Circ_0061395 functions as an oncogenic gene in hepatocellular carcinoma by acting as a miR-1182 sponge[J]. Cell Cycle, 2022, 21(20): 2192-2205. DOI: 10.1080/15384101.2022.2092177.
[9]	LIU J, HE X, ZOU Y, et al. Circular RNA circ-STIL contributes to cell growth and metastasis in hepatocellular carcinoma via regulating miR-345-5p/AQP3 axis[J]. Dig Dis Sci, 2022, 67(6): 2269-2282. DOI: 10.1007/s10620-021-07054-7.
[10]	LIU Y, XIAO X, WANG J, et al. Silencing circEIF3I/miR-526b-5p axis epigenetically targets HGF/c-Met signal to hinder the malignant growth, metastasis and angiogenesis of hepatocellular carcinoma[J]. Biochem Genet, 2023, 61(1): 48-68. DOI: 10.1007/s10528-022-10239-y.
[11]	JU A, SHEN Y, YUE A. Circ_0011232 contributes to hepatocellular carcinoma progression through miR-503-5p/AKT3 axis[J]. Hepatol Res, 2022, 52(6): 532-545. DOI: 10.1111/hepr.13758.
[12]	ZHAO Z, HE J, FENG C. CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis[J]. Immunol Res, 2022, 70(3): 341-353. DOI: 10.1007/s12026-021-09255-8.
[13]	RAZPOTNIK R, VIDMAR R, FONOVIĆ M, et al. Circular RNA hsa_circ_0062682 binds to YBX1 and promotes oncogenesis in hepatocellular carcinoma[J]. Cancers (Basel), 2022, 14(18): 4524. DOI: 10.3390/cancers14184524.
[14]	DONG W, DAI ZH, LIU FC, et al. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production[J]. EBioMedicine, 2019, 45: 155-167. DOI: 10.1016/j.ebiom.2019.06.030.
[15]	PENG R, CAO J, SU BB, et al. Down-regulation of circPTTG1IP induces hepatocellular carcinoma development via miR-16-5p/RNF125/JAK1 axis[J]. Cancer Lett, 2022, 543: 215778. DOI: 10.1016/j.canlet.2022.215778.
[16]	LU Y, ZHANG J, WU Y. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis[J]. Mol Med Rep, 2021, 24(2): 609. DOI: 10.3892/mmr.2021.12247.
[17]	GUO X, WANG Z, DENG X, et al. Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184[J]. Cell Cycle, 2022, 21(15): 1557-1577. DOI: 10.1080/15384101.2022.2057633.
[18]	FENG KL, DIAO N, ZHOU ZW, et al. CircFGGY inhibits cell growth, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma via regulating the miR-545-3p/Smad7 axis[J]. Front Cell Dev Biol, 2022, 10: 850708. DOI: 10.3389/fcell.2022.850708.
[19]	LI G, KONG J, DONG S, et al. Circular BANP knockdown inhibits the malignant progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation[J]. Chin Med J (Engl), 2022. DOI: 10.1097/CM9.00000000000001822.[Online ahead of print]
[20]	LIU H, LAN T, LI H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR[J]. Theranostics, 2021, 11(3): 1396-1411. DOI: 10.7150/thno.53227.
[21]	WANG L, LONG H, ZHENG Q, et al. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression[J]. Mol Cancer, 2019, 18(1): 119. DOI: 10.1186/s12943-019-1046-7.
[22]	ZHANG PF, GAO C, HUANG XY, et al. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma[J]. Mol Cancer, 2020, 19(1): 110. DOI: 10.1186/s12943-020-01222-5.
[23]	HUANG M, HUANG X, HUANG N. Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells[J]. Cancer Sci, 2022, 113(6): 1968-1983. DOI: 10.1111/cas.15365.
[24]	CAO P, MA B, SUN D, et al. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis[J]. Cancer Sci, 2022, 113(2): 634-647. DOI: 10.1111/cas.15238.
[25]	WANG Y, GAO R, LI J, et al. Downregulation of hsa_circ_0074854 suppresses the migration and invasion in hepatocellular carcinoma via interacting with HuR and via suppressing exosomes-mediated macrophage M2 polarization[J]. Int J Nanomedicine, 2021, 16: 2803-2818. DOI: 10.2147/IJN.S284560.
[26]	LI Q, PAN X, ZHU D, et al. Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 axis under hypoxic stress[J]. Hepatology, 2019, 70(4): 1298-1316. DOI: 10.1002/hep.30671.
[27]	ZHANG B, LIU Z, CAO K, et al. Circ-SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR-33a to promote hepatocellular carcinoma tumorigenesis[J]. Cancer Med, 2020, 9(16): 5999-6008. DOI: 10.1002/cam4.3219.
[28]	LIU W, YIN C, LIU Y. Circular RNA circ_0091579 promotes hepatocellular carcinoma proliferation, migration, invasion, and glycolysis through miR-490-5p/CASC3 axis[J]. Cancer Biother Radiopharm, 2021, 36(10): 863-878. DOI: 10.1089/cbr.2019.3472.
[29]	LI J, HU ZQ, YU SY, et al. CircRPN2 inhibits aerobic glycolysis and metastasis in hepatocellular carcinoma[J]. Cancer Res, 2022, 82(6): 1055-1069. DOI: 10.1158/0008-5472.CAN-21-1259.
[30]	CHEN Z, DU J, YANG C, et al. circ-CFH promotes the development of HCC by regulating cell proliferation, apoptosis, migration, invasion, and glycolysis through the miR-377-3p/RNF38 axis[J]. Open Life Sci, 2022, 17(1): 248-260. DOI: 10.1515/biol-2022-0029.
[31]	CHEN X, SHE P, WANG C, et al. Hsa_circ_0001806 promotes glycolysis and cell progression in hepatocellular carcinoma through miR-125b/HK2[J]. J Clin Lab Anal, 2021, 35(12): e23991. DOI: 10.1002/jcla.23991.
[32]	YANG Q, WU G. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression[J]. Gastroenterol Hepatol, 2022, 45(10): 742-752. DOI: 10.1016/j.gastrohep.2021.11.007.
[33]	LI Y, ZHANG Y, ZHANG S, et al. circRNA circARNT2 suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting the miR-155-5p/PDK1 axis[J]. Mol Ther Nucleic Acids, 2021, 23: 244-254. DOI: 10.1016/j.omtn.2020.08.037.
[34]	WANG S, LIU D, WEI H, et al. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating Reelin gene expression[J]. Bioengineered, 2022, 13(2): 2272-2284. DOI: 10.1080/21655979.2021.2024332.
[35]	LU JC, ZHANG PF, HUANG XY, et al. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma[J]. J Hematol Oncol, 2021, 14(1): 200. DOI: 10.1186/s13045-021-01207-x.
[36]	HUANG H, PENG J, YI S, et al. Circular RNA circUBE2D2 functions as an oncogenic factor in hepatocellular carcinoma sorafenib resistance and glycolysis[J]. Am J Transl Res, 2021, 13(6): 6076-6086.
[37]	WENG H, ZENG L, CAO L, et al. circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324[J]. Mol Ther Nucleic Acids, 2021, 23: 811-820. DOI: 10.1016/j.omtn.2020.12.019.
[38]	LI J, QIN X, WU R, et al. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis[J]. J Cell Mol Med, 2020, 24(9): 5152-5161. DOI: 10.1111/jcmm.15162.
[39]	LI Y, LI R, CHENG D, et al. The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma[J]. PeerJ, 2022, 10: e13640. DOI: 10.7717/peerj.13640.
[40]	DU N, LI K, WANG Y, et al. CircRNA circBACH1 facilitates hepatitis B virus replication and hepatoma development by regulating the miR-200a-3p/MAP3K2 axis[J]. Histol Histopathol, 2022, 37(9): 863-877. DOI: 10.14670/HH-18-452.
[41]	HE W, ZHU X, TANG X, et al. Circ_0027089 regulates NACC1 by targeting miR-136-5p to aggravate the development of hepatitis B virus-related hepatocellular carcinoma[J]. Anticancer Drugs, 2022, 33(1): e336-e348. DOI: 10.1097/CAD.0000000000001211.
[42]	CHEN Y, LI S, WEI Y, et al. Circ-RNF13, as an oncogene, regulates malignant progression of HBV-associated hepatocellular carcinoma cells and HBV infection through ceRNA pathway of circ-RNF13/miR-424-5p/TGIF2[J]. Bosn J Basic Med Sci, 2021, 21(5): 555-568. DOI: 10.17305/bjbms.2020.5266.
[43]	ZHU M, LIANG Z, PAN J, et al. Hepatocellular carcinoma progression mediated by hepatitis B virus-encoded circRNA HBV_circ_1 through interaction with CDK1[J]. Mol Ther Nucleic Acids, 2021, 25: 668-682. DOI: 10.1016/j.omtn.2021.08.011.
[44]	WANG Y, PEI L, YUE Z, et al. The potential of serum exosomal hsa_circ_0028861 as the novel diagnostic biomarker of HBV-derived hepatocellular cancer[J]. Front Genet, 2021, 12: 703205. DOI: 10.3389/fgene.2021.703205.
[45]	SONG Y, CAO P, LI J. Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors[J]. J Clin Lab Anal, 2021, 35(11): e24009. DOI: 10.1002/jcla.24009.
[46]	EL SHARKAWI FZ, AWAD MS, ELAGAWY W, et al. Circular RNAs 0064286 and 0000475: potential diagnostic biomarkers in hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(9): 3039-3044. DOI: 10.31557/APJCP.2021.22.9.3039.
[47]	NIE G, PENG D, LI B, et al. Diagnostic accuracy of serum/plasma circular RNAs and the combination of circular RNAs and α-fetoprotein for detecting hepatocellular carcinoma: A Meta-analysis[J]. Front Genet, 2021, 12: 722208. DOI: 10.3389/fgene.2021.722208.
[48]	ZHANG Y, LI J, CUI Q, et al. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma[J]. Bioengineered, 2022, 13(2): 1988-2003. DOI: 10.1080/21655979.2021.2006952.
[49]	CHEN G, XIE D, ZHANG P, et al. Circular RNA hsa_circ_0000437 may be used as a new indicator for the diagnosis and prognosis of hepatocellular carcinoma[J]. Bioengineered, 2022, 13(6): 14118-14124. DOI: 10.1080/21655979.2022.2081458.
[50]	ZHANG P, SUN H, WEN P, et al. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma[J]. Mol Ther Nucleic Acids, 2022, 27: 293-303. DOI: 10.1016/j.omtn.2021.12.001.
[51]	KIM G, HAN JR, PARK SY, et al. Circular noncoding RNA hsa_circ_0005986 as a prognostic biomarker for hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 14930. DOI: 10.1038/s41598-021-94074-y.
[52]	LEE T, PAQUET M, LARSSON O, et al. Tumor cell survival dependence on the DHX9 DExH-box helicase[J]. Oncogene, 2016, 35(39): 5093-5105. DOI: 10.1038/onc.2016.52.
[53]	ZHOU S, WEI J, WANG Y, et al. Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma[J]. Exp Ther Med, 2020, 19(4): 2733-2740. DOI: 10.3892/etm.2020.8526.

Relative Articles

[1]	Yannan LI, Changzheng LI. Gut microbiota in hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(3): 552-555. doi: 10.12449/JCH250324
[2]	Li HUO, Zhihui CHANG. Role of biliary microbiota in the development and progression of common biliary tract diseases[J]. Journal of Clinical Hepatology, 2024, 40(8): 1699-1703. doi: 10.12449/JCH240831
[3]	Yijie ZHAO, Lu XIE, Yating ZHANG, Guangwei LIU. Pyroptosis： A new bridge connecting gut microbiota and liver diseases[J]. Journal of Clinical Hepatology, 2024, 40(9): 1908-1915. doi: 10.12449/JCH240930
[4]	Guirong CHEN, Minggang WANG, Huaming LIN, Huiping YAN, Xiufeng WANG. Changes and pathogenic mechanism of intestinal flora in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(8): 1992-1998. doi: 10.3969/j.issn.1001-5256.2023.08.034
[5]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[6]	Fuchun WANG, Ziyi LI, Wanjie ZHANG, Xiaorong MAO, Junfeng LI. The significance of gut microbiota in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(7): 1667-1670. doi: 10.3969/j.issn.1001-5256.2022.07.040
[7]	Yingyu LE, Rongzhen ZHANG, Weisong XIAO, Xiaobin QIN, Shenglan ZENG, Dewen MAO. Gut microbiota regulation and diet therapy for hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1694-1698. doi: 10.3969/j.issn.1001-5256.2021.07.046
[8]	Tao LI, Panliang WANG, Zibo YUAN, Quankai FENG, Jie LI. Changes in intestinal flora in patients with extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2883-2889. doi: 10.3969/j.issn.1001-5256.2021.12.029
[9]	An GAO, Yujing XU, Shengwei LU, Wei SUN, Jianhe GAN. Effect of fecal microbiota transplantation on intestinal flora in mice with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2021, 37(6): 1379-1385. doi: 10.3969/j.issn.1001-5256.2021.06.031
[10]	Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
[11]	Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
[12]	Ceng ShengLan, Lu: Chao, Xiao WeiSong, Tan XiaoBin, Wu Cong, Mao DeWen. Mechanism of action of intestinal flora in hepatic encephalopathy and related treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(10): 2375-2379. doi: 10.3969/j.issn.1001-5256.2020.10.047
[13]	Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
[14]	Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
[15]	Li Zhen, Zhang Wei, Jia Lin, Hu ZhongJie. Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces[J]. Journal of Clinical Hepatology, 2020, 36(4): 900-903. doi: 10.3969/j.issn.1001-5256.2020.04.042
[16]	Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
[17]	Wang DanDan, Song Jia, Zhang XiaoLan. Research advances in the role of gut microbiota in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(9): 2120-2123. doi: 10.3969/j.issn.1001-5256.2019.09.053
[18]	Gao Hui, Liu ShouSheng, Zhao ZhenZhen, Xin YongNing. Role of intestinal flora-mediated immune response in chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2019, 35(11): 2565-2568. doi: 10.3969/j.issn.1001-5256.2019.11.039
[19]	Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	杨鸣，李艳敏. 自身免疫性肝炎患者免疫球蛋白水平与肝脏炎症程度相关性. 社区医学杂志. 2021(14): 857-860 .
2.	户梅芳. 肝功能和自身抗体检查在自身免疫性肝炎诊断中的应用探讨. 淮海医药. 2019(01): 62-64 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (504) PDF downloads(27)

Role of circular RNA in the development, progression, diagnosis, and treatment of hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.08.033